Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview

The Top Line

Despite the long holiday weekend, news in biopharma never slows down.

In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week.

On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still delivering strong sales growth despite emerging uncertainties in Washington, D.C., a few major players are starting to see a slowdown. Each company tells a different story, and Sagonowsky and Dunleavy dive into the nuances of the current commercial landscape.

Later, Fierce Biotech's Gabrielle Masson and Darren Incorvaia highlight key data from the American Society of Gene & Cell Therapy conference and preview what the team is watching at this week’s American Society of Clinical Oncology annual meeting.

To learn more about the topics in this episode:

• Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms
• Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2
• ASGCT: Analysts see Rocket gene therapy setting 'a new bar' for efficacy in heart condition
• Rocket crashes as gene therapy patient dies, FDA imposes hold

This episode is sponsored by Cencora.

See omnystudio.com/listener for privacy information.